Introduction
Though short courses of acyclovir, used in intravenous,'2 oral,3-5 and topical formulations6"0 are of clinical benefit in treating first and recurrent episodes of genital herpes, they do not appear to influence the incidence of future recurrences.
Acyclovir prophylaxis of herpes simplex virus (HSV) infections has been successfully used in immunocompromised patients;' '-'5 recent studies in immune competent patients have also shown an appreciably reduced incidence of genital recurrences in parallel groups of patients treated with continuous oral acyclovir compared with placebo. '6-'8 In this randomised double blind crossover study our objective was to compare in the same patients the efficacy and safety of continuous oral acyclovir with apparently identical placebo in preventing recurrences of genital herpes.
PAtients and methods

STUDY POPULATION
Men and women aged 18 or more attending the department of genitourinary medicine, Royal Hallamshire Hospital, Sheffield, who had had six or more recurrences of genital herpes in the preceding year were eligible for the study; patients who were enrolled had experienced at least one documented culture positive episode in the preceding two months. All patients had normal renal and hepatic function and none had received recent antiviral or immune stimulatory treatment. Women who were pregnant or using inadequate contraception were excluded.
STUDY DESIGN
Patients were entered into the study within 72 hours of the onset of a recurrence. They were randomly allocated to a first treatment course consisting of 387 analysed by fitting a linear model to the data using maximum likelihood estimation in which the effects due to sex, treatment and its duration, and patient differences were considered.
Results
NUMBER OF PATIENTS AND THEIR CHARACTERISTICS
From a total of 40 patients (24 men and 16 women) enrolled into the study, 28 (16 men and 12 women) completed the scheduled treatment with both acyclovir and placebo.
Of the 12 patients who were excluded from the efficacy analysis, six defaulted from follow up (three while taking acyclovir, three while taking placebo), one was withdrawn because of failure to comply with the protocol, two did not experience a subsequent recurrence during the study period after completing their first treatment period (one after taking acyclovir, the other after taking placebo), and three were withdrawn after the development of adverse events during treatment (two taking acyclovir, one taking placebo).
The mean age of entrants to the study was 29-4 (range 18 to 52) years, the median number of yearly recurrences was 12 (range six to 40), and the median duration of genital herpes before enrolment was three (range one to 12 years).
HSV 2 isolates were obtained from 38 patients and HSV 1 from three patients; one patient yielded both HSV 2 and HSV 1.
EFFICACY OF ACYCLOVIR
Two of the 28 patients who completed the trial did not experience a recurrence while being treated with either acyclovir or placebo. The other 26 patients experienced a recurrence while receiving placebo, and only three of them experienced a recurrence while receiving acyclovir (table 1). In two of these patients the failure to comply with medication was a contributory factor initiating recurrence: in one a recurrence developed five days after supplies of medication ran out while she was on holiday, in the thrombosis as the cause of her symptoms"Wtren acyclovir was recommenced, the same symptoms recurred after three days; treatment was the terminated. A man asked to be withdrawn from the study while taking acyclovir because of persistent headache, joint pains, and sore eyes; clinical examination showed no abnormality, and his. symptoms were not thought to be related to the treatment. Transient episodes of penile discomfort or erythema and flatulence, or all three, were reported by two patients, of drowsiness by one patient, and of conjunctivitis by one patient. These conditions resolved despite continuation of acyclovir. During placebo treatment, one patient was withdrawn from the study when severe depression developed. Transient conjunctivitis occurred in another patient.
A statistical analysis of blood chemistry and haematology data showed no significant differences in the occurrence of abnormal measurements recorded for each treatment group. Though there were significantly lower total protein concentrations (p = 0-04) and red cell counts (p = 0-03) and a trend towards higher erythrocyte sedimentation rates (p = 009) when acyclovir was used, the differences between mean values, which remained well within their normal ranges, were small and not considered to be of clinical importance.
VIRAL SENSITIVITIES BEFORE AND AFTER TAKING ACYCLOVIR
Viral isolates were tested before and after patients took acyclovir. In 10 patients both sets of isolates remained within the expected range for sensitive virus (IC50 < 2 mg/l). In a further six patients from whom viral isolates were tested only after taking acyclovir, the IC50 also remained < 2 mg/l.
Discussion
The results of this crossover study show that 389 390 G R Kinghorn, M Jeavons, M Rowland, I Abeywickreme, I G Barton, C W Potter, and E A Hickmott continuous oral acyclovir 200 mg four times a day is effective in preventing recurrent genital herpes. They confirm other recent reports in which efficacy was assessed by comparisons between parallel groups of patients treated with either acyclovir or placebo. I5-8 Only three of 28 of our patients developed recurrences during acyclovir treatment; in all three patients viral isolates after treatment remained sensitive to acyclovir. In two of the apparent treatment failures there was evidence of compliance problems; and in both of these patients, who were subsequently entered into an open study, acyclovir has been completely effective in suppressing recurrences for 12 months when given in the same dosage. Successful treatment with acyclovir for periods of 84 days, however, does not affect the natural history of the disease once treatment is discontinued. The time to first recurrence after treatment with acyclovir was similar to that in patients who were taking placebo.
Prophylactic treatment with acyclovir was not associated with serious side effects. No definite causal relation was established between acyclovir and adverse events necessitating withdrawal of the drug. Though statistical analysis of blood chemistry and haematological data showed appreciably lower total protein concentrations and red blood cell counts when acyclovir was used, this does not necessarily imply clinical importance. Mean values for these variables remained within the normal ranges for our laboratories. Furthermore, for a study of this size at least one result may be expected to attain statistical significance purely by chance, and it is possible that the observed differences may be unrelated to treatment.
Concern has been expressed about the possible emergence or selection of acyclovir resistant viruses during prophylactic treatment.'7120 We found that all isolates taken before treatment with acyclovir were fully sensitive to the drug, and that isolates taken after treatment showed no appreciable change in sensitivity to acyclovir. Nevertheless, it would seem wise to advocate that selected centres should continue sensitivity testing of viral isolates from patients undergoing long term acyclovir prophylaxis to investigate further this possibility.
In summary, we have confirmed the efficacy and safety of oral acyclovir prophylaxis of recurrent genital herpes. As treatment for up to 12 weeks does not appear to influence the natural history of genital herpes once the drug has been discontinued, studies to assess efficacy and safety during and after longer courses of acyclovir are desirable. The present high cost of maintenance treatment with oral acyclovir is likely to preclude its usefulness in all but those patients who are severely incapacitated by very frequent recurrences.
